“According to the International Foundation of Employee Benefit Plans’ 2026 employer survey, more than 90% of employers cover GLP-1s for diabetes. But only 36% also cover them to treat obesity.”
Fewer employers are covering GLP-1 drugs for weight loss. Should they?marketplace.org
Same drugs, two rules: more than 90% of employers cover GLP-1s for diabetes, only 36% for obesity. Which side you land on can come down to whether an A1c reads 6.4 or 6.5, and that's a strange place to hang a coverage decision. I get that price is the real problem. I just don't think the diagnosis line is an honest way to ration it.